These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 24052043)

  • 1. The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance.
    Toner AP; McLaughlin F; Giles FJ; Sullivan FJ; O'Connell E; Carleton LA; Breen L; Dunne G; Gorman AM; Lewis JD; Glynn SA
    Br J Cancer; 2013 Oct; 109(8):2131-41. PubMed ID: 24052043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells.
    Wang H; Vo T; Hajar A; Li S; Chen X; Parissenti AM; Brindley DN; Wang Z
    BMC Cancer; 2014 Jan; 14():37. PubMed ID: 24447372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells.
    Souchek JJ; Davis AL; Hill TK; Holmes MB; Qi B; Singh PK; Kridel SJ; Mohs AM
    Mol Cancer Ther; 2017 Sep; 16(9):1819-1830. PubMed ID: 28615298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes.
    Mumenthaler SM; Ng PY; Hodge A; Bearss D; Berk G; Kanekal S; Redkar S; Taverna P; Agus DB; Jain A
    Mol Cancer Ther; 2009 Oct; 8(10):2882-93. PubMed ID: 19825806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression of AXL enhances docetaxel-resistance of prostate cancer cells].
    Lin JZ; Zhu JG; Wu HF; Li JM; DE W; Wang ZJ
    Zhonghua Nan Ke Xue; 2017 Apr; 23(4):302-308. PubMed ID: 29714413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer.
    Ahn S; Hwang DJ; Barrett CM; Yang J; Duke CB; Miller DD; Dalton JT
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):293-304. PubMed ID: 20383708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
    Sampath D; Greenberger LM; Beyer C; Hari M; Liu H; Baxter M; Yang S; Rios C; Discafani C
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3459-69. PubMed ID: 16740771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure.
    Makarovskiy AN; Siryaporn E; Hixson DC; Akerley W
    Cell Mol Life Sci; 2002 Jul; 59(7):1198-211. PubMed ID: 12222966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of docetaxel and vandetanib in docetaxel-sensitive or resistant PC3 cell line.
    Monteverde M; Tonissi F; Fischel JL; Etienne-Grimaldi MC; Milano G; Merlano M; Lo Nigro C
    Urol Oncol; 2013 Aug; 31(6):776-86. PubMed ID: 21795074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition.
    Iannelli F; Roca MS; Lombardi R; Ciardiello C; Grumetti L; De Rienzo S; Moccia T; Vitagliano C; Sorice A; Costantini S; Milone MR; Pucci B; Leone A; Di Gennaro E; Mancini R; Ciliberto G; Bruzzese F; Budillon A
    J Exp Clin Cancer Res; 2020 Oct; 39(1):213. PubMed ID: 33032653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer.
    Li X; Gera L; Zhang S; Chen Y; Lou L; Wilson LM; Xie ZR; Sautto G; Liu D; Danaher A; Mamouni K; Yang Y; Du Y; Fu H; Kucuk O; Osunkoya AO; Zhou J; Wu D
    Theranostics; 2021; 11(14):6873-6890. PubMed ID: 34093859
    [No Abstract]   [Full Text] [Related]  

  • 12. 2-Phenyl-5-(pyrrolidin-1-yl)-1-(3,4,5-trimethoxybenzyl)-1H-benzimidazole, a benzimidazole derivative, inhibits growth of human prostate cancer cells by affecting tubulin and c-Jun N-terminal kinase.
    Chang WL; Chang CS; Chiang PC; Ho YF; Liu JF; Chang KW; Guh JH
    Br J Pharmacol; 2010 Aug; 160(7):1677-89. PubMed ID: 20649571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABCB1-mediated docetaxel resistance reversed by erastin in prostate cancer.
    Chen F; Wu S; Kuang N; Zeng Y; Li M; Xu C
    FEBS J; 2024 Jul; 291(14):3249-3266. PubMed ID: 38712529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterisation and manipulation of docetaxel resistant prostate cancer cell lines.
    O'Neill AJ; Prencipe M; Dowling C; Fan Y; Mulrane L; Gallagher WM; O'Connor D; O'Connor R; Devery A; Corcoran C; Rani S; O'Driscoll L; Fitzpatrick JM; Watson RW
    Mol Cancer; 2011 Oct; 10():126. PubMed ID: 21982118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.
    Alshaker H; Wang Q; Kawano Y; Arafat T; Böhler T; Winkler M; Cooper C; Pchejetski D
    Oncotarget; 2016 Dec; 7(49):80943-80956. PubMed ID: 27821815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel-resistant prostate cancer cells remain sensitive to S-trityl-L-cysteine-mediated Eg5 inhibition.
    Wiltshire C; Singh BL; Stockley J; Fleming J; Doyle B; Barnetson R; Robson CN; Kozielski F; Leung HY
    Mol Cancer Ther; 2010 Jun; 9(6):1730-9. PubMed ID: 20515952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner.
    Pinto AC; Moreira JN; Simões S
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):445-54. PubMed ID: 19104815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo.
    Ikezoe T; Hisatake Y; Takeuchi T; Ohtsuki Y; Yang Y; Said JW; Taguchi H; Koeffler HP
    Cancer Res; 2004 Oct; 64(20):7426-31. PubMed ID: 15492266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
    Li X; Wu JB; Chung LW; Huang WC
    Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-kappaB.
    Kim SM; Lee SY; Cho JS; Son SM; Choi SS; Yun YP; Yoo HS; Yoon DY; Oh KW; Han SB; Hong JT
    Eur J Pharmacol; 2010 Apr; 631(1-3):1-9. PubMed ID: 20056115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.